Ask AI
Beyond Initial Response

CE / CME

Beyond Initial Response: Long-term Monitoring and Management in MASH

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: July 14, 2025

Expiration: July 13, 2026

Activity

Progress
1 2
Course Completed

Mr Rodgers returns for follow-up 4 months after recommitting to full-dose incretin-based therapy and continues to demonstrate excellent adherence to both lifestyle and pharmacologic management. At this visit, his weight remains stable with a sustained 11% loss, A1C is 6.5% (previously 6.6%), liver enzymes show mild improvement but remain elevated (ALT 45 U/L, AST 40 U/L), and VCTE reveals liver stiffness has plateaued at 7.5 kPa, unchanged from the prior reading. He is asymptomatic and remains highly motivated. Although his metabolic markers are stable, there is no additional improvement in hepatic fibrosis or inflammation, prompting consideration of whether therapeutic intensification is warranted to drive further histologic benefit, particularly in light of emerging data on newer agents

What is the most appropriate next step in managing Mr Rodgers’ therapy at this time?